Get the Stockscreener App
33.05
0.78%
-0.2573
Ideaya Biosciences Inc stock is traded at $33.05, with a volume of 44,097.
It is down -0.78% in the last 24 hours and up +0.45% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
See More
Previous Close:
$33.31
Open:
$32.78
24h Volume:
44,097
Relative Volume:
0.05
Market Cap:
$2.90B
Revenue:
$218.71M
Net Income/Loss:
$-113.70M
P/E Ratio:
-25.36
EPS:
-1.3034
Net Cash Flow:
$-73.47M
1W Performance:
+0.67%
1M Performance:
+0.45%
6M Performance:
+28.39%
1Y Performance:
+81.49%
1-Day Range:
$32.78
$33.37
1-Week Range:
$32.15
$35.27
52-Week Range:
$13.45
$39.28
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
33.08 | 2.93B | 218.71M | -113.70M | -73.47M | -1.3034 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.48 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.04 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
685.06 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.85 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.42 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Initiated | Truist | Buy |
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Sep-04-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-22-25 | Initiated | TD Cowen | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-26-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Nov-05-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Mar-08-24 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | SVB Securities | Outperform |
| May-24-23 | Initiated | Goldman | Buy |
| Apr-24-23 | Upgrade | Stifel | Hold → Buy |
| Mar-23-23 | Initiated | Berenberg | Buy |
| Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-28-22 | Initiated | CapitalOne | Overweight |
| Oct-27-22 | Initiated | Citigroup | Buy |
| Aug-15-22 | Downgrade | Stifel | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-10-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-11-21 | Initiated | Guggenheim | Buy |
| Oct-07-20 | Initiated | Wedbush | Outperform |
| Sep-01-20 | Initiated | Northland Capital | Outperform |
| Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-06-20 | Initiated | H.C. Wainwright | Buy |
| Mar-13-20 | Initiated | ROTH Capital | Buy |
| Oct-17-19 | Initiated | Oppenheimer | Outperform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Jun-17-19 | Initiated | Citigroup | Buy |
| Jun-17-19 | Initiated | JP Morgan | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and IDEAYA Biosciences (IDYA) - The Globe and Mail
IDEAYA Biosciences (IDYA) Gets a Buy from Mizuho Securities - The Globe and Mail
Three experimental cancer programs to watch at April's big AACR meeting - Stock Titan
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
IDEAYA Biosciences, Inc. $IDYA Shares Purchased by Cinctive Capital Management LP - MarketBeat
Iron Triangle Partners LP Makes New Investment in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
A Look At IDEAYA Biosciences (IDYA) Valuation After IDE892 Trial Enrollment And Pipeline Refocus - simplywall.st
IDEAYA Biosciences, Inc. $IDYA Position Increased by Baker BROS. Advisors LP - MarketBeat
IDEAYA Biosciences Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
42,283 Shares in IDEAYA Biosciences, Inc. $IDYA Bought by WINTON GROUP Ltd - MarketBeat
Truist reiterates Ideaya Biosciences stock rating on MTAP program By Investing.com - Investing.com Canada
IDEAYA Biosciences: Expanding Precision Oncology Platform and Refocused MTAP Strategy Support Buy Rating - TipRanks
Ideaya Biosciences announces first-patient-in for phase 1 trial of IDE892 - marketscreener.com
Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892 - TradingView
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update – Company Announcement - Financial Times
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update - Sahm
IDEAYA Biosciences announces the latest development timeline for its Cdkn2a project - Bitget
IDYA SEC FilingsIdeaya Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
(IDYA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Goldman Sachs Maintains IDEAYA Biosciences (IDYA) Neutral Recommendation - MSN
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC - finance.yahoo.com
Aug Mood: What is IDEAYA Biosciences Incs P E ratio telling usJuly 2025 Action & Fast Gain Stock Tips - baoquankhu1.vn
Fisher Asset Management LLC Lowers Stock Holdings in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDYA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up on Insider Buying Activity - MarketBeat
IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: A Biotech Gem With 51% Upside Potential - DirectorsTalk Interviews
Did IDEAYA’s (IDYA) First-in-Human IDE034 Trial Just Redefine Its Targeted Oncology Strategy? - simplywall.st
Ideaya Biosciences Insider Bought Shares Worth $1,647,890, According to a Recent SEC Filing - marketscreener.com
Insider Buying: IDEAYA Biosciences (NASDAQ:IDYA) Director Buys 50,000 Shares of Stock - MarketBeat
Ideaya Biosciences (IDYA) director Stein buys $1.65 million in stock By Investing.com - Investing.com Australia
Ideaya Biosciences (IDYA) director Stein buys $1.65 million in stock - Investing.com
Director Jeffrey Stein buys 50,000 IDEAYA Biosciences (IDYA) shares in market - Stock Titan
IDEAYA Biosciences Director Jeffrey Stein Acquires 50,000 Shares - TradingView
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - The AI Journal
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 - Via TT
Assessing IDEAYA Biosciences (IDYA) Valuation After IDE034 First-In-Human Dosing Milestone - Yahoo Finance
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 - lelezard.com
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 – News Hub - Medianet News Hub
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
Fifth Lane Capital LP Invests $932,000 in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Ideaya Biosciences announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Evaluating IDEAYA Biosciences (IDYA) Valuation As Recent Volatility Sends Mixed Signals - simplywall.st
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific Top1 ADC - marketscreener.com
(IDYA) Risk Channels and Responsive Allocation - Stock Traders Daily
Ideaya Biosciences announces first-patient-in for phase 1 trial of IDE034, a potential first-in-class B7h3/Ptk7 bispecific Top1 ADC - marketscreener.com
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC - The AI Journal
Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of Ide034, A Potential First-In-Class B7h3/Ptk7 Bispecific Top1 Adc - TradingView
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC – Company Announcement - Financial Times
Dual-target cancer drug enters human tests, aimed at lung, breast and colon - Stock Titan
IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: Unlocking A Potential 58% Upside - DirectorsTalk Interviews
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):